Vectus Biosystems Ltd

NEW
ASX:VBS (Australia)  
A$ 0.050 +0.013 (+35.14%) Jul 18
At Loss
P/B:
6.26
Market Cap:
A$ 2.66M ($ 1.74M)
Enterprise V:
A$ 1.88M ($ 1.23M)
Volume:
65.74K
Avg Vol (2M):
91.79K
Trade In:
Volume:
65.74K
At Loss
Avg Vol (2M):
91.79K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Vectus Biosystems Ltd ( ASX:VBS ) from 2016 to Jul 19 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vectus Biosystems stock (ASX:VBS) PE ratio as of Jul 19 2025 is 0. More Details

Vectus Biosystems Ltd (ASX:VBS) PE Ratio (TTM) Chart

To

Vectus Biosystems Ltd (ASX:VBS) PE Ratio (TTM) Historical Data

Total 1180
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Vectus Biosystems PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2025-07-19 At Loss 0 0 0 2025-05-16 At Loss 0 0 0
2025-07-18 At Loss 0 0 0 2025-05-15 At Loss 0 0 0
2025-07-17 At Loss 0 0 0 2025-05-14 At Loss 0 0 0
2025-07-16 At Loss 0 0 0 2025-05-13 At Loss 0 0 0
2025-07-15 At Loss 0 0 0 2025-05-12 At Loss 0 0 0
2025-07-14 At Loss 0 0 0 2025-05-09 At Loss 0 0 0
2025-07-11 At Loss 0 0 0 2025-05-08 At Loss 0 0 0
2025-07-10 At Loss 0 0 0 2025-05-07 At Loss 0 0 0
2025-07-09 At Loss 0 0 0 2025-05-06 At Loss 0 0 0
2025-07-08 At Loss 0 0 0 2025-05-05 At Loss 0 0 0
2025-07-07 At Loss 0 0 0 2025-05-02 At Loss 0 0 0
2025-07-04 At Loss 0 0 0 2025-05-01 At Loss 0 0 0
2025-07-03 At Loss 0 0 0 2025-04-30 At Loss 0 0 0
2025-07-02 At Loss 0 0 0 2025-04-29 At Loss 0 0 0
2025-07-01 At Loss 0 0 0 2025-04-28 At Loss 0 0 0
2025-06-30 At Loss 0 0 0 2025-04-25 At Loss 0 0 0
2025-06-27 At Loss 0 0 0 2025-04-24 At Loss 0 0 0
2025-06-26 At Loss 0 0 0 2025-04-23 At Loss 0 0 0
2025-06-25 At Loss 0 0 0 2025-04-22 At Loss 0 0 0
2025-06-24 At Loss 0 0 0 2025-04-21 At Loss 0 0 0
2025-06-23 At Loss 0 0 0 2025-04-18 At Loss 0 0 0
2025-06-20 At Loss 0 0 0 2025-04-17 At Loss 0 0 0
2025-06-19 At Loss 0 0 0 2025-04-16 At Loss 0 0 0
2025-06-18 At Loss 0 0 0 2025-04-15 At Loss 0 0 0
2025-06-17 At Loss 0 0 0 2025-04-14 At Loss 0 0 0
2025-06-16 At Loss 0 0 0 2025-04-11 At Loss 0 0 0
2025-06-13 At Loss 0 0 0 2025-04-10 At Loss 0 0 0
2025-06-12 At Loss 0 0 0 2025-04-09 At Loss 0 0 0
2025-06-11 At Loss 0 0 0 2025-04-08 At Loss 0 0 0
2025-06-10 At Loss 0 0 0 2025-04-07 At Loss 0 0 0
2025-06-06 At Loss 0 0 0 2025-04-04 At Loss 0 0 0
2025-06-05 At Loss 0 0 0 2025-04-03 At Loss 0 0 0
2025-06-04 At Loss 0 0 0 2025-04-02 At Loss 0 0 0
2025-06-03 At Loss 0 0 0 2025-04-01 At Loss 0 0 0
2025-06-02 At Loss 0 0 0 2025-03-31 At Loss 0 0 0
2025-05-30 At Loss 0 0 0 2025-03-28 At Loss 0 0 0
2025-05-29 At Loss 0 0 0 2025-03-27 At Loss 0 0 0
2025-05-28 At Loss 0 0 0 2025-03-26 At Loss 0 0 0
2025-05-27 At Loss 0 0 0 2025-03-25 At Loss 0 0 0
2025-05-26 At Loss 0 0 0 2025-03-24 At Loss 0 0 0
2025-05-23 At Loss 0 0 0 2025-03-21 At Loss 0 0 0
2025-05-22 At Loss 0 0 0 2025-03-20 At Loss 0 0 0
2025-05-21 At Loss 0 0 0 2025-03-19 At Loss 0 0 0
2025-05-20 At Loss 0 0 0 2025-03-18 At Loss 0 0 0
2025-05-19 At Loss 0 0 0 2025-03-17 At Loss 0 0 0

Vectus Biosystems Ltd (ASX:VBS) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.